Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo.
Animals
Benzamides
/ administration & dosage
Female
Gamma Rhythm
/ drug effects
Histone Deacetylase Inhibitors
/ administration & dosage
Histone Deacetylases
/ physiology
Hydroxamic Acids
/ administration & dosage
Male
Membrane Potentials
/ drug effects
Neurons
/ drug effects
Pedunculopontine Tegmental Nucleus
/ drug effects
Pyridines
/ administration & dosage
Pyrroles
/ administration & dosage
Rats, Sprague-Dawley
Arousal
Calcium channels. Calcium currents
Gamma oscillations
MC1568
MS275
Neuroepigenetics
Trichostatin A
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
received:
03
07
2019
revised:
28
11
2019
accepted:
20
12
2019
pubmed:
11
1
2020
medline:
31
3
2021
entrez:
11
1
2020
Statut:
ppublish
Résumé
The pedunculopontine nucleus (PPN) has long been known to be part of the reticular activating system (RAS) in charge of arousal and REM sleep. We previously showed that in vitro exposure to a HDAC Class I and II mixed inhibitor (TSA), or a specific HDAC class IIa inhibitor (MC 1568), decreased PPN gamma oscillations. Given the lack of information on systemic in vivo treatments on neuronal synaptic properties, the present study was designed to investigate the systemic effect of HDAC inhibitors (HDACi) on PPN rhythmicity. Rat pups were injected (acute, single dose) with TSA (4 or 20 mg/kg), MC1568 (4 or 20 mg/kg), or MS275 (20 or 100 mg/kg). Our results show that MC1568 (20 mg/kg) reduced mean frequency of PPN oscillations at gamma band, while increasing mean input resistance (Rm) of PPN neurons. For TSA (4 and 20 mg/kg), we observed reduced mean frequency of oscillations at gamma band and increased mean Rm of PPN neurons. Systemic administration of 20 mg/kg MC1568 and TSA effects on Rm were washed out after 60 min of in vitro incubation of PPN slices, suggesting an underlying functional recovery of PPN calcium-mediated gamma band oscillations over time. In addition, at a lower dose, 4 mg/kg, MC1568 and TSA induced higher mean amplitude gamma oscillations. Blocking HDAC class I might not have deleterious effects on gamma activity, but, more importantly, the inhibition of HDAC class I (at 100 mg/kg) increased gamma band oscillations. In conclusion, the present results in vivo validate our previous findings in vitro and further expand information on the effects of HDAC inhibition on PPN rhythmicity. PPN neurons require normal activity of HDAC class IIa in order to oscillate at gamma band.
Identifiants
pubmed: 31923766
pii: S0028-3908(19)30493-9
doi: 10.1016/j.neuropharm.2019.107922
pmc: PMC7029427
mid: NIHMS1548786
pii:
doi:
Substances chimiques
Benzamides
0
Histone Deacetylase Inhibitors
0
Hydroxamic Acids
0
MC1568
0
Pyridines
0
Pyrroles
0
entinostat
1ZNY4FKK9H
trichostatin A
3X2S926L3Z
Histone Deacetylases
EC 3.5.1.98
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107922Subventions
Organisme : NIGMS NIH HHS
ID : P30 GM110702
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
J Neurophysiol. 2015 Feb 1;113(3):709-19
pubmed: 25376789
J Neurophysiol. 2010 May;103(5):2417-32
pubmed: 20181729
J Neurosci. 2015 May 13;35(19):7332-48
pubmed: 25972164
Nat Rev Cancer. 2001 Dec;1(3):194-202
pubmed: 11902574
Radiother Oncol. 1995 Sep;36(3):225-8
pubmed: 8532910
Clin Cancer Res. 2008 May 15;14(10):3113-23
pubmed: 18483379
Drug Metab Dispos. 2004 Oct;32(10):1132-8
pubmed: 15269190
J Neurophysiol. 2012 Feb;107(3):772-84
pubmed: 22090455
Acta Neuropathol. 2016 Oct;132(4):487-502
pubmed: 27282474
Sci Rep. 2018 Sep 3;8(1):13156
pubmed: 30177751
Neuroscience. 2019 Jun 1;408:339-348
pubmed: 31022463
Immunol Cell Biol. 2012 Jan;90(1):39-46
pubmed: 22083525
Heliyon. 2019 Aug 28;5(8):e02265
pubmed: 31497668
Expert Rev Anticancer Ther. 2010 Jun;10(6):935-54
pubmed: 20553216
Pharmacol Ther. 2015 May;149:150-90
pubmed: 25550231
Mol Neurobiol. 2018 Jan;55(1):222-228
pubmed: 28840475
Trends Pharmacol Sci. 2017 Apr;38(4):363-377
pubmed: 28139258
Front Neurol. 2013 Nov 06;4:176
pubmed: 24223570
Neuroscience. 2018 May 21;379:228-238
pubmed: 29588251
Science. 2009 Aug 14;325(5942):834-40
pubmed: 19608861
Toxicol Sci. 2016 Dec;154(2):227-240
pubmed: 27660204
Sleep. 2008 May;31(5):673-90
pubmed: 18517037
PLoS One. 2017 Mar 30;12(3):e0174763
pubmed: 28358909
Neurobiol Dis. 2013 Jan;49:177-89
pubmed: 22971966
Eur J Neurosci. 2009 Jan;29(2):340-58
pubmed: 19200238
Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C282-C288
pubmed: 31747316
Sleep. 2007 Nov;30(11):1405-14
pubmed: 18041475
Nat Rev Genet. 2009 Jan;10(1):32-42
pubmed: 19065135
J Neurophysiol. 2010 Jul;104(1):463-74
pubmed: 20463196
Int J Hematol. 2016 Sep;104(3):300-9
pubmed: 27099225
Exp Neurobiol. 2019 Aug 31;28(4):504-515
pubmed: 31495079
Cell Res. 2007 Mar;17(3):195-211
pubmed: 17325692
Eur J Neurosci. 2011 Aug;34(3):404-15
pubmed: 21722210
Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767
pubmed: 27713375
Mol Biol Cell. 2000 Jun;11(6):2069-83
pubmed: 10848630
J Neural Transm (Vienna). 2016 Jul;123(7):655-665
pubmed: 26597124